These results compare nicely with previous data from our group demonstrating that genetic or pharmacological blockade of SF3B1, another key component for spliceosome function, can reduce HCC aggressiveness in vitro and in vivo8 and provide additional support for the relationship between the dysregulated splicing process and HCC development and progression6. Here, SF3B1 is linked to hepatocellular carcinoma.